Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Boston Oncology

Request full access

Generics, Emerging Markets, Biosimilars | Boston Oncology

Cambridge, United StatesFounded 2005Biotech & Life Sciences

About Boston Oncology

Boston Oncology operates as a biogenerics company with a focus on licensing, local development, manufacturing, and distribution of pharmaceuticals across various therapeutic areas. The company was founded in 2012 by Dr. Abdullah Baaj with the mission to provide cost-effective, locally-produced therapeutics for cancers and inflammatory diseases in emerging nations. While it has headquarters in Cambridge, Massachusetts, its operational nerve center is in Riyadh, Saudi Arabia.

The company's business model centers on acquiring intellectual property and transferring technology to localize the manufacturing of generic chemotherapy and biologic pharmaceuticals in developing nations and emerging markets. This is exemplified by its GCC entity, Boston Oncology Arabia, which serves as a key part of its strategy and is aligned with Saudi Arabia's Vision 2030 by enhancing local healthcare services and manufacturing capabilities. A significant milestone was achieved in July 2024 when Boston Oncology Arabia secured a $35 million investment from TVM Capital Healthcare to advance its manufacturing facility in Sudair Industrial City. The company generates revenue through the commercialization of its licensed and locally produced medicines.

Initially concentrating on oncology, the company has since broadened its portfolio to include critical care, specialty generics, anti-infectives, and biosimilars. A key achievement has been the rapid expansion of its product portfolio approved by the Saudi Food and Drug Authority (SFDA), growing from zero in 2018 to a projected 61 by 2022, with a target of over 175 products. Its manufacturing facility in Saudi Arabia is GMP-certified and has an annual capacity of over 30 million vials. Boston Oncology serves government hospitals and is a preferred supplier to institutions like the King Faisal Specialist Hospital. In January 2025, a partnership was announced with SPIMACO to localize the production of oral oncology treatments in Saudi Arabia, further strengthening the region's pharmaceutical infrastructure.

Source: Dealroom company data

Boston Oncology in the Cambridge ecosystem

Live from Dealroom

The Boston Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • TVM Capital Healthcare
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇸🇦 Saudi Arabia71.9%
🇮🇳 India25.6%
🇺🇸 United States1.6%
🇵🇰 Pakistan0.8%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Boston Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Boston Oncology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.